AnjaliTOwensMD
Cardiology • Philadelphia, PAAdult Congenital Heart Disease, Cardiac Electrophysiology, Heart Failure & Transplantation, Interventional Cardiology
Assistant Professor, Medicine, Perelman School of Medicine
Dr. Owens is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3400 Spruce St
Philadelphia, PA 19104Phone+1 215-314-0343
Education & Training
University of Pennsylvania Health SystemFellowship, Cardiovascular Disease, 2010 - 2011- University of Pennsylvania Health SystemFellowship, Cardiovascular Disease, 2007 - 2010
- University of Pennsylvania Health SystemResidency, Internal Medicine, 2003 - 2006
Duke University School of MedicineClass of 2003, B.A.
Certifications & Licensure
PA State Medical License 2003 - 2026
American Board of Internal Medicine Advanced Heart Failure and Transplant Cardiology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- HCMR - Novel Markers of Prognosis in Hypertrophic Cardiomyopathy
- DCM Precision Medicine Study Start of enrollment: 2016 Jun 07
Publications & Presentations
PubMed
- Valsartan and Cardiac Remodeling in Early-Stage Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial Cardiac Magnetic Resonance Substudy.John W Ostrominski, Brian L Claggett, Michael Jerosch-Herold, Anna Axelsson Raja, Sharlene M Day
JAMA Cardiology. 2025-03-05 - Genome-wide association study meta-analysis provides insights into the etiology of heart failure and its subtypes.Albert Henry, Xiaodong Mo, Chris Finan, Mark D Chaffin, Doug Speed
Nature Genetics. 2025-03-04 - 6 citationsMavacamten-Associated Temporal Changes in Left Atrial Function in Obstructive HCM: Insights From the VALOR-HCM Trial.Milind Y Desai, Yuichiro Okushi, Kathy Wolski, Jeffrey B Geske, Anjali Owens
JACC. Cardiovascular Imaging. 2025-03-01
Journal Articles
- Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients with Heart Failure with Reduced Ejection Fraction in US Clinical PracticeMuthiah Vaduganathan, Javed Butler, Paul A Heidenreich, Michelle M Kittleson, Anjali Tiku Owens, Pamela N Peterson, Clyde W Yancy, Gregg C Fonarow, JAMA Cardiology
Authored Content
- Diagnosis of Hypertrophic Cardiomyopathy: What Every Cardiologist Needs to KnowFebruary 2020
- Diagnosis of Hypertrophic Cardiomyopathy: What Every Cardiologist Needs to KnowFebruary 2020
Press Mentions
Cytokinetics Presents Additional Data from SEQUOIA-HCM at the HCMS Scientific SessionsSeptember 27th, 2024- U.S. Food and Drug Administration Approves Camzyos™ (Mavacamten) for the Treatment of Adults with Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and SymptomsApril 29th, 2022
- FDA Approves Mavacamten, First Treatment for Obstructive Hypertrophic CardiomyopathyApril 29th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
